# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price targe...
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-res...
Argus Research analyst Jasper Hellweg maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target ...
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named C...